

GRAIL, Inc. Class Action Lawsuit

U.S. Securities Litigation

GRAIL Complaint Overview

The GRAIL class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GRAIL common stock. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned *Robbins v. GRAIL, Inc., et al.*, No. 26-cv-05428.

If you lost money on your GRAIL investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is GRAIL Being Sued for Securities Fraud?

GRAIL has been sued for securities fraud following a significant stock drop resulting from potential violations of the federal securities laws. The decline in GRAIL's stock price caused significant losses to investors.

GRAIL is a commercial-stage healthcare company focused on early cancer detection. GRAIL developed Galleri, a multi-cancer early detection test that analyzes blood samples to screen for multiple cancers, identify the likely organ or tissue of origin, and assist in the screening process. As part of GRAIL's efforts to attain an accelerated implementation of its test as a national screening program through the United Kingdom's National Health Service ("NHS"), GRAIL conducted the "NHS-Galleri trial." The primary objective of the NHS-Galleri trial was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not."

According to the complaint, during the relevant period, GRAIL made positive statements about Galleri, the NHS-Galleri trial design, and top-line results from the first screening round, including that the NHS-Galleri trial was "designed with three

consecutive years of screening in order to achieve the primary endpoint,” and that “Galleri is working in the real world.”

As alleged, in truth, the NHS-Galleri trial’s three-year timeframe was insufficient to demonstrate the primary endpoint.

Why did GRAIL’s Stock Drop?

On February 19, 2026, GRAIL announced top-line results from its NHS-Galleri trial. Although the Company emphasized certain favorable results, GRAIL disclosed that the trial did not meet its primary endpoint. Specifically, GRAIL stated that the “primary endpoint of statistically significant Stage III-IV reduction was not observed.” GRAIL attributed the disappointing outcome, in part, to “probably need[ing] a longer follow-up time to be able to [compare the two arms of the study] adequately.”

This news caused the price of GRAIL stock to decline \$51.32 per share, or 50.55%, from a closing price of \$101.53 per share on February 19, 2026, to \$50.21 per share on February 20, 2026.

GRAIL, Inc. (GRAL) Stock Chart




Image Caption: [NASDAQ online chart](#) showing the GRAIL, Inc.’s (GRAL) stock drop following the February 2026 revelation.

What is the GRAIL Leadership Deadline?

You may ask the Court no later than August 4, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information for the GRAIL Class Action?

If you lost money when GRAIL common stock dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall
amccall@bfalaw.com
212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*.

BFA attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, “Litigation Stars” by *Benchmark Litigation*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360*, and “SuperLawyers” by *Thomson Reuters*.

BFA’s notable successes include a recovery of over \$900 million in value from Tesla, Inc.’s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.

